WO2024083820A1 - Method and composition for determining the level of o-glcnacylation in horses - Google Patents
Method and composition for determining the level of o-glcnacylation in horses Download PDFInfo
- Publication number
- WO2024083820A1 WO2024083820A1 PCT/EP2023/078823 EP2023078823W WO2024083820A1 WO 2024083820 A1 WO2024083820 A1 WO 2024083820A1 EP 2023078823 W EP2023078823 W EP 2023078823W WO 2024083820 A1 WO2024083820 A1 WO 2024083820A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glcnacylation
- sepsis
- compound
- levels
- risk
- Prior art date
Links
- 230000006271 O-GlcNAcylation Effects 0.000 title claims abstract description 76
- 238000000034 method Methods 0.000 title claims abstract description 40
- 241000283086 Equidae Species 0.000 title abstract description 39
- 239000000203 mixture Substances 0.000 title description 20
- 206010040047 Sepsis Diseases 0.000 claims abstract description 70
- 241000283073 Equus caballus Species 0.000 claims abstract description 40
- 210000004369 blood Anatomy 0.000 claims abstract description 17
- 239000008280 blood Substances 0.000 claims abstract description 17
- 239000012472 biological sample Substances 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims description 70
- 238000012360 testing method Methods 0.000 claims description 36
- 102100030122 Protein O-GlcNAcase Human genes 0.000 claims description 20
- 108010045982 hexosaminidase C Proteins 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 239000000523 sample Substances 0.000 claims description 12
- 239000003112 inhibitor Substances 0.000 claims description 10
- LFTYTUAZOPRMMI-CFRASDGPSA-N UDP-N-acetyl-alpha-D-glucosamine Chemical compound O1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](NC(=O)C)[C@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-CFRASDGPSA-N 0.000 claims description 9
- LFTYTUAZOPRMMI-UHFFFAOYSA-N UNPD164450 Natural products O1C(CO)C(O)C(O)C(NC(=O)C)C1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 LFTYTUAZOPRMMI-UHFFFAOYSA-N 0.000 claims description 9
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 7
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 5
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 4
- 229960002442 glucosamine Drugs 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 3
- PPAIMZHKIXDJRN-FMDGEEDCSA-N (3ar,5r,6s,7r,7ar)-2-(ethylamino)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]2O PPAIMZHKIXDJRN-FMDGEEDCSA-N 0.000 claims description 2
- 208000004998 Abdominal Pain Diseases 0.000 abstract description 19
- 101001120790 Caenorhabditis elegans UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase Proteins 0.000 abstract description 19
- 208000002881 Colic Diseases 0.000 abstract description 18
- 238000001262 western blot Methods 0.000 abstract description 10
- 230000007423 decrease Effects 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 5
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 5
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108010017384 Blood Proteins Proteins 0.000 description 4
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108010077991 O-GlcNAc transferase Proteins 0.000 description 2
- 102000005520 O-GlcNAc transferase Human genes 0.000 description 2
- 229940126137 O-GlcNAcase inhibitor Drugs 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- -1 for example Chemical class 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000004768 organ dysfunction Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 229960001153 serine Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- GSXOAOHZAIYLCY-UHFFFAOYSA-N D-F6P Natural products OCC(=O)C(O)C(O)C(O)COP(O)(O)=O GSXOAOHZAIYLCY-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 101150081099 OGA gene Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- BGWGXPAPYGQALX-ARQDHWQXSA-N beta-D-fructofuranose 6-phosphate Chemical compound OC[C@@]1(O)O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O BGWGXPAPYGQALX-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000008383 multiple organ dysfunction Effects 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000018299 prostration Diseases 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000030133 remittent fever Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000002366 time-of-flight method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 208000037911 visceral disease Diseases 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/38—Post-translational modifications [PTMs] in chemical analysis of biological material addition of carbohydrates, e.g. glycosylation, glycation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Definitions
- the invention is in the field of horses, more particularly the invention relates to method and composition for determining the O-GlcNAcylation blood level in horses.
- Digestive diseases are among the most important diseases in horses, both from a medical and economic point of view (Archer et Proudman 2006). They can be responsible for considerable economic and sporting losses for the equine sector due to their frequency and possible complications (Taylor 2015). While in many cases they resolve with medical treatment in the field, for some horses they can become the leading cause of death, especially when associated with a serious complication such as sepsis. It is defined as organ dysfunction caused by a deregulated host response to infection (Singer et al., 2016).
- the invention relates to a method for diagnosing whether a horse is at risk of or is susceptible to have a risk of sepsis comprising following steps: i) quantifying the expression level of O-GlcNAcylation in a biological sample obtained from the horse; ii) comparing the expression level quantified at step i) with its predetermined reference value; and iii) concluding that the horse is at risk of or is susceptible to have a risk of sepsis when the expression level of O-GlcNAcylation quantified at step i) is lower than its predetermined reference value.
- Blood sample and clinical data were collected at admission to the equine emergency service of Oniris and during the 3 first days of hospitalization. O-GlcNAc levels in blood were evaluated by western blot. Data were analyzed with ImageLab and Prism software.
- O-GlcNAc levels are 2 times higher in colic induced sepsis group than in control or colic groups (control 0.65 ⁇ 0.42; colic 0.55 ⁇ 0.13; sepsis 1.09 ⁇ 0.35, p ⁇ 0.05 Mann-Whitney test). O-GlcNAc levels decrease by 80% over time in septic horses (p ⁇ 0.05 One way-ANOVA test).
- O-GlcNAc levels in septic horses tended to decrease between admission and the first day (DI) after admission. This decrease became significant from the second day (D2) of hospitalization (Control D2: 80.52 ⁇ 52.04; Sepsis D2: 27.86 ⁇ 28.40, p ⁇ 0.05; Control D3: 84.91 ⁇ 51.30; Sepsis D3: 27.86 ⁇ 30.33, p ⁇ 0.01 Two way ANOVA test with repeated measure).
- the invention relates to a method for diagnosing whether a horse is at risk of or is susceptible to have a risk of sepsis comprising following steps: i) quantifying the expression level of O-GlcNAcylation in a biological sample obtained from the horse; ii) comparing the expression level quantified at step i) with its predetermined reference value; and iii) concluding that the horse is at risk of or is susceptible to have a risk of sepsis when the expression level of O-GlcNAcylation quantified at step i) is lower than its predetermined reference value.
- the invention relates to a method for diagnosing whether a horse is at risk of or is susceptible to have a risk of sepsis comprising following steps: i) quantifying the expression level of O-GlcNAcylation in a biological sample obtained from the horse at the admission and/or at the first day (DI) after admission; ii) quantifying the expression level of O-GlcNAcylation in a biological sample obtained from the horse at 2h, 4h, 6h, 8h, lOh, 12h, 14h, 16h, 18h, 20h, 22h, 24h, 26h, 28h, 30h, 32h, 34h, 36h, 38h, 40h, 42h, 44h, 44h, 46h or 48h after admission; iii) comparing the expression level quantified at step i) with the expression level quantified at step ii) and iv) concluding that the horse is at risk of or is susceptible to have a risk of sepsis when the expression level
- step ii) is performed at second day (D2) after admission.
- diagnosis refers to classifying a disease or a symptom, determining a severity of the disease, monitoring disease progression, forecasting an outcome of a disease and/or prospects of recovery.
- the present invention relates to a method for diagnosing sepsis in a horse.
- sepsis means morbid condition induced by a toxin, the introduction or accumulation of which is caused by infection or trauma, and includes the early stage of sepsis, severe sepsis and the acute phase of septic shock. Sepsis is one of the complication of colic.
- colic encompasses all forms of gastrointestinal conditions which cause pain as well as other causes of abdominal pain not involving the gastrointestinal tract. The most common forms of colic are gastrointestinal in nature and are most often related to colonic disturbance.
- stage sepsis refers to the stage of the disease with the onset of clinical symptoms of severe infectious disease that typically include chills, profuse sweat, irregularly remittent fever, prostration and the like.
- severe sepsis refers to the stage of the disease with the clinical symptoms of early stage sepsis in addition to persistent fever, lymphopenia, disseminated intravascular coagulation, respiratory distress syndrome, multiple organ failure and hypotension leading to shock.
- acute phase of septic shock refers to peripheral circulatory collapse, resulting in hemodynamic, metabolic and visceral disorders that almost invariably lead to death.
- risk refers to the probability that an event will occur over a specific time period, as in the conversion to sepsis, and can mean a subject's "absolute” risk or “relative” risk.
- Absolute risk can be measured with reference to either actual observation postmeasurement for the relevant time cohort, or with reference to index values developed from statistically valid historical cohorts that have been followed for the relevant time period.
- Relative risk refers to the ratio of absolute risks of a subject compared either to the absolute risks of low risk cohorts or an average population risk, which can vary by how clinical risk factors are assessed.
- Odds ratios the proportion of positive events to negative events for a given test result, are also commonly used (odds are according to the formula p/(l- p) where p is the probability of event and (1- p) is the probability of no event) to no conversion.
- Alternative continuous measures which may be assessed in the context of the present invention, include time to sepsis conversion risk reduction ratios.
- Risk evaluation in the context of the present invention encompasses making a prediction of the probability, odds, or likelihood that an event or disease state may occur, the rate of occurrence of the event or conversion from one disease state to another, i.e., from a normal condition to a sepsis condition or to one at risk of developing a sepsis.
- Risk evaluation can also comprise prediction of future clinical parameters, traditional laboratory risk factor values, or other indices of sepsis, such as cellular population determination in peripheral tissues, in serum or other fluid, either in absolute or relative terms in reference to a previously measured population.
- the methods of the present invention may be used to make continuous or categorical measurements of the risk of conversion to sepsis, thus diagnosing and defining the risk spectrum of a category of subjects defined as being at risk for a sepsis.
- the invention can be used to discriminate between normal and other subject cohorts at higher risk for sepsis.
- the present invention may be used so as to help to discriminate those having sepsis from normal.
- O-GlcNAcylation also known as O-N-acetyl glucosaminylation refers to a reversible posttranslational modification (PTM) that involves the addition of the monosaccharide b-D-Nacetylglucosamine to serine and threonine residues of proteins.
- PTM posttranslational modification
- Protein O-GlcNAcylation is catalyzed by O-GlcNAc transferase (OGT), and the O- GlcNAc group on proteins can be removed with the catalysis of P-N-acetylglucosaminidase (O- GlcNAcase, OGA).
- O-GlcNAcylation is regulated dynamically by these two enzymes and by the intracellular concentration of UDP-GlcNAc, a product of glucose metabolism through the hexosamine biosynthetic pathway (HBP).
- HBP hexosamine biosynthetic pathway
- the term “level of O-GlcNAcylation” refers to the expression or level of O-GlcNAcylation in the biological sample.
- the said expression level may be expressed as any arbitrary unit that reflects the amount of the protein of interest that has been detected in the biological sample, such as intensity of a radioactive or of a fluorescence signal emitted by a labeled antibody specifically bound to the protein of interest.
- the value obtained at the end of step a) may consist of a concentration of protein(s) of interest that could be measured by various protein detection methods well known in the art, such as ELISA, SELDI-TOF, FACS or Western blotting.
- blood proteins were extracted according to the protocol used by lin and collaborators.
- Western blots were performed on the protein extracts using an antibody directed against the O-GlcNAc (Ac-RL2-HRP ref : 201995 Abeam). Briefly proteins were quantified using a BCA protein assay kit. 25 mg of each sample was separated on an SDS-PAGE gel and transferred to a nitrocellulose membrane. The membranes were blocked with 3% Bovine serum albumin (BSA) in TBS IX -Tween 0.5X (TBS-T) and then incubated with Anti-O-Linked N-acetylglucosamine antibody (clone RL2, 1 :20 000) overnight at 4°C. Analyses were performed using Image Lab software (Bio-Rad, California, United States). A ratio to the stain-free intensity was calculated.
- BSA Bovine serum albumin
- the horse is at risk of or is susceptible to have a risk of sepsis when the level of O-GlcNAcylation decreases at two days after admission at hospital.
- the term “biological sample” refers to any sample obtained from a horse, such as a serum sample, a plasma sample, a urine sample, a blood sample, a lymph sample, or a tissue sample.
- the biological sample is a blood sample obtained from the horse.
- the term “predetermined reference value” refers to a threshold value or a cut-off value. In the context of the invention, the predetermined reference value refers to the expression level of O-GlcNAcylation measured at step i). Typically, the predetermined reference value corresponds to the level of O-GlcNAc level at the admission.
- the expression level of O-GlcNAcylation measured at step i) relates to the quantification of O-GlcNAc level at admission and/or the first day (DI) after admission.
- the expression level of O-GlcNAcylation measured at step ii) relates to the quantification of O-GlcNAc level at second day (D2) of hospitalization.
- a “threshold value” or “cut-off value” can be determined experimentally, empirically, or theoretically.
- a threshold value can also be arbitrarily selected based upon the existing experimental and/or clinical conditions, as would be recognised by a person of ordinary skilled in the art. For example, retrospective measurement of the O-GlcNAcylation level in properly banked historical subject samples may be used in establishing the reference value.
- the threshold value has to be determined in order to obtain the optimal sensitivity and specificity according to the function of the test and the benefit/risk balance (clinical consequences of false positive and false negative).
- the optimal sensitivity and specificity can be determined using a Receiver Operating Characteristic (ROC) curve based on experimental data.
- ROC Receiver Operating Characteristic
- ROC curve is receiver operator characteristic curve, which is also known as receiver operation characteristic curve. It is mainly used for clinical biochemical diagnostic or prognostic tests. ROC curve is a comprehensive indicator that reflects the continuous variables of true positive rate (sensitivity) and false positive rate (1- specificity). It reveals the relationship between sensitivity and specificity with the image composition method. A series of different cut-off values (thresholds or critical values, boundary values between normal and abnormal results of diagnostic test) are set as continuous variables to calculate a series of sensitivity and specificity values.
- ROC curve such as: MedCalc 9.2.0.1 medical statistical software, SPSS 9.0, ROCPOWER.SAS, DESIGNROC.FOR, MULTIREADER POWER. SAS, CREATE-ROC.SAS, GB STAT VIO.O (Dynamic Microsystems, Inc. Silver Spring, Md., USA), Stata/Se version 12.0 software (StataCorp LP, College Station, TX, USA), etc.
- the reference value is the level of O-GlcNAcylation in a healthy subject (i.e that has not been diagnosed for a sepsis). In some embodiments, the reference value is the level of O-GlcNAcylation detected in previous samples obtained from the subject. In some embodiment, the reference value is the upper limit of values determined in healthy subjects (i.e that has not been diagnosed for a sepsis).
- the invention in a second aspect, relates to a method for increasing O-GlcNAcylation levels in a horse having or is susceptible to have a sepsis comprising administering said horse with a therapeutically effective amount of a compound that increases O-GlcNAcylation level.
- the invention relates to a method for treating sepsis in a horse comprising administering said horse with a therapeutically effective amount of a compound that increases O-GlcNAcylation level.
- the method according to the invention wherein the horse is diagnosed as having a risk of sepsis according to the method described as above.
- the method according to the invention wherein the compound that increases O-GlcNAcylation level is administered when the horse has a low expression level of O-GlcNAcylation during the second time.
- increasing refers to an increase in O-GlcNAcylation levels.
- an increase in O-GlcNAcylation levels allows to reduce production of lactates, creatininemia and blood urea nitrogen (BUN) and arterial bicarbonates.
- the term “compound that increases O-GlcNAcylation levels” refers to a natural or synthetic compound that has a biological effect to increase the levels of - GlcNAcylation.
- the compound that increases O-GlcNAcylation levels is a peptide, peptidomimetic or a small organic molecule.
- the compound that increases O-GlcNAcylation levels is a small organic molecule.
- small organic molecule refers to a molecule of a size comparable to those organic molecules generally used in pharmaceuticals. The term excludes biological macromolecules (e.g., proteins, nucleic acids, etc.). Preferred small organic molecules range in size up to about 5000 Da, more preferably up to 2000 Da, and most preferably up to about 1000 Da.
- the compound that increases O-GlcNAcylation levels is 1,2- dideoxy-2 z -propyl- a -d-glucopyranoso-[2, 1-D]- A 2-thiazoline (NButGT) and its derivatives. The CAS number of NButGT is 863918-55-2.
- the compound that increases O-GlcNAcylation levels is (3aR,5R,6S,7R,7aR)-2-(ethylamino)-3a,6,7,7a-tetrahydro-5-(hydroxymethyl)-5H-Pyrano[3,2- d]thiazole-6,7-diol) (ThiametG) and its derivatives.
- the CAS number of ThiametG is 1009816- 48-1.
- the compound that increases O-GlcNAcylation levels is a compound that increases the Uridine diphosphate N-acetylglucosamine (UDP-GlcNAc).
- UDP-GlcNAc refers to a nucleotide sugar and a coenzyme in metabolism. It is synthesized de novo from glucose by the hexosamine synthesis pathway (HXBP), but can also be produced via salvage pathways.
- HXBP hexosamine synthesis pathway
- the compound that increases O-GlcNAcylation levels is UDP-GlcNAc.
- compound that increases O-GlcNAcylation levels is a ccompound that increases the hexosamine biosynthesis pathway flux that bypasses glutamine/fructose-6-phosphate amidotransferase 2.
- the compound that increases O-GlcNAcylation levels is glutamine or glucosamine.
- the compound that increases O-GlcNAcylation levels is an inhibitor of O-GlcNAcase (OGA).
- OAA O-GlcNAcase
- O-GlcNAcase is an enzyme with systematic name (protein)- 3-O-(N-acetyl-D-glucosaminyl)-L-serine/threonine N-acetylglucosaminyl hydrolase.
- OGA is encoded by the OGA gene. This enzyme catalyzes the removal of the O-GlcNAc post- translational modification. OGA catalyzes O-GlcNAc hydrolysis via an oxazoline reaction intermediate.
- Inhibitor of OGA is well known in the art. Tests for determining the capacity of a compound to be OGA inhibitor are well known to the person skilled in the art.
- the inhibitor specifically binds to OGA in a sufficient manner to inhibit the biological activity of OGA. Binding to OGA and inhibition of the biological activity OGA may be determined by any competing assays well known in the art.
- the assay may consist in determining the ability of the agent to be tested as OGA inhibitor to bind to OGA. The binding ability is reflected by the Kd measurement. .
- KD is intended to refer to the dissociation constant, which is obtained from the ratio of Kd to Ka (i.e. Kd/Ka) and is expressed as a molar concentration (M). KD values for binding biomolecules can be determined using methods well established in the art.
- the inhibitor of OGA is selected from the group consisting of but not limited to: MK-8719, LY3372689 or ASN-120,290 and their derivatives.
- the inhibitor of OGA is MK-8719 as described in Seinick et al 2019 (DOI: 10.1021/acs.jmedchem.9b01090; J. Med. Chem. 2019, 62, 10062-10097).
- the inhibitor of OGA is LY3372689 as described in WO2018/140299 and in Shcherbinin et al 2020 (Alzheimer's & Dementia: The Journal of the Alzheimer's Association , Dec2020 Supplement SI 1, Vol. 16 Issue 11, pl-2, 2p. Publisher: John Wiley & Sons, Inc).
- the inhibitor of OGA is ASN-120,290 (previously ASN- 561) as described in WO2017/144639.
- the inhibitor of OGA is described in W02006/092049, WO 2008/025170, W02010/012106, WO2010/012106, W02010/012107, WO2010/037207, WO201 1/140640, W02012/064680, WO2012/083435, WO2013/166654, W02014/100934, WO2014/032184, WO2014/032185, WO2014/032187, WO2014/067003, WO2017106254, and WO2022/108377.
- administering refers to the act of injecting or otherwise physically delivering a substance as it exists outside the body (e.g., a compound that increases O-GlcNAcylation levels) into the subject, such as by mucosal, intradermal, intravenous, subcutaneous, intramuscular delivery and/or any other method of physical delivery described herein or known in the art.
- a disease, or a symptom thereof is being treated, administration of the substance typically occurs after the onset of the disease or symptoms thereof.
- administration of the substance typically occurs before the onset of the disease or symptoms thereof.
- a “therapeutically effective amount” is intended for a minimal amount of active agent which is necessary to impart therapeutic benefit to a subject.
- a “therapeutically effective amount” to a subject is such an amount which induces, ameliorates or otherwise causes an improvement in the pathological symptoms, disease progression or physiological conditions associated with or resistance to succumbing to a disorder. It will be understood that the total daily usage of the compounds of the present invention will be decided by the attending physician within the scope of sound medical judgment.
- the specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific compound 15 employed; the specific composition employed, the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts.
- the daily dosage of the products may be varied over a wide range from 0.01 to 1,000 mg per adult per day.
- the compositions contain 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 250 and 500 mg of the active ingredient for the symptomatic adjustment of the dosage to the subject to be treated.
- a medicament typically contains from about 0.01 mg to about 500 mg of the active ingredient, preferably from 1 mg to about 100 mg of the active ingredient.
- An effective amount of the drug is ordinarily supplied at a dosage level from 0.0002 mg/kg to about mg/kg of body weight per day, especially from about 0.001 mg/kg to 7 mg/kg of body weight per day.
- the compound that increases O-GlcNAcylation levels as described above may be combined with pharmaceutically acceptable excipients, and optionally sustained-release matrices, such as biodegradable polymers, to form pharmaceutical compositions.
- the invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a compound that increases O-GlcNAcylation levels.
- the invention relates to the pharmaceutical composition comprising a compound that increases O-GlcNAcylation levels for use in the treatment of sepsis in horse.
- the invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising the compound that increases O-GlcNAcylation levels as described above and excipients.
- “Pharmaceutically” or “pharmaceutically acceptable” refer to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to a mammal, especially a human, as appropriate.
- a pharmaceutically acceptable carrier or excipient refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
- the pharmaceutical compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, transdermal, local or rectal administration, the active principle, alone or in combination with another active principle, can be administered in a unit administration form, as a mixture with conventional pharmaceutical supports, to animals and human beings.
- Suitable unit administration forms comprise oral-route forms such as tablets, gel capsules, powders, granules and oral suspensions or solutions, sublingual and buccal administration forms, aerosols, implants, subcutaneous, transdermal, topical, intraperitoneal, intramuscular, intravenous, subdermal, transdermal, intrathecal and intranasal administration forms and rectal administration forms.
- the pharmaceutical compositions contain vehicles which are pharmaceutically acceptable for a formulation capable of being injected.
- saline solutions monosodium or disodium phosphate, sodium, potassium, calcium or magnesium chloride and the like or mixtures of such salts
- dry, especially freeze-dried compositions which upon addition, depending on the case, of sterilized water or physiological saline, permit the constitution of injectable solutions.
- the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations including sesame oil, peanut oil or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists.
- Solutions comprising compounds of the invention as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
- the polypeptide (or nucleic acid encoding thereof) can be formulated into a composition in a neutral or salt form.
- Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.
- inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like.
- Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine,
- the carrier can also be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetables oils.
- the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
- isotonic agents for example, sugars or sodium chloride.
- Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminium monostearate and gelatin.
- Sterile injectable solutions are prepared by incorporating the active polypeptides in the required amount in the appropriate solvent with several of the other ingredients enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
- sterile powders for the preparation of sterile injectable solutions
- the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective.
- the formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above, but drug release capsules and the like can also be employed.
- parenteral administration in an aqueous solution for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
- aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
- sterile aqueous media which can be employed will be known to those of skill in the art in light of the present disclosure.
- one dosage could be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion. Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.
- the invention relates to a pharmaceutical composition comprising NButGT in the context of sepsis in horse.
- the invention relates to a pharmaceutical composition comprising ThiametG in the context of sepsis in horse.
- the invention relates to a pharmaceutical composition comprising glutamine or glucosamine in the context of sepsis in horse.
- the invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising MK-8719, LY3372689 or ASN-120,290 and their derivatives
- a further object of the present invention relates to a method of screening a compound that increases O-GlcNAcylation levels comprising i) providing a test compound and ii) determining the ability of said test compound to increase O-GlcNAcylation levels.
- the assay first comprises determining the ability of the test compound to bind to a protein O-GlcNAcylation.
- a population of cells is then contacted and activated so as to determine the ability of the test compound to increase O-GlcNAcylation.
- the effect triggered by the test compound is determined relative to that of a population of immune cells incubated in parallel in the absence of the test compound or in the presence of a control agent either of which is analogous to a negative control condition.
- control substance refers a molecule that is inert or has no activity relating to an ability to modulate a biological activity or expression. It is to be understood that test compounds capable of increasing O-GlcNAcylation levels, as determined using in vitro methods described herein, are likely to exhibit similar modulatory capacity in applications in vivo.
- the test compound is small organic molecules.
- the test compound according to the invention may be selected from a library of compounds previously synthesised, or a library of compounds for which the structure is determined in a database, or from a library of compounds that have been synthesised de novo. In some embodiments, the test compound may be selected form small organic molecules.
- the invention relates to a kit suitable diagnosis whether a horse is at risk of or is susceptible to have a risk of sepsis comprising a reagent that specifically reacts with O-GlcNAcylation and instructions to perform the diagnosing method of sepsis according to the method as described above.
- the invention in another aspect, relates to a method of screening a compound that increases O-GlcNAcylation levels comprising i) providing a test compound and ii) determining the ability of said test compound to increase O-GlcNAcylation levels.
- Any biological assay well known in the art could be suitable for determining the ability of the test compound to increase the O-GlcNAcylation levels.
- the assay first comprises determining the ability of the test compound to bind to O-GlcNAcylation level.
- a population of cells is then contacted and activated so as to determine the ability of the test compound to increase the O-GlcNAcylation levels.
- control substance refers a molecule that is inert or has no activity relating to an ability to modulate a biological activity or expression. It is to be understood that test compounds capable of increasing the O-GlcNAcylation levels, as determined using in vitro methods described herein, are likely to exhibit similar modulatory capacity in applications in vivo.
- the test compound is selected from the group consisting of peptides, petptidomimetics, small organic molecules, aptamers or nucleic acids.
- the test compound according to the invention may be selected from a library of compounds previously synthesised, or a library of compounds for which the structure is determined in a database, or from a library of compounds that have been synthesised de novo.
- the test compound may be selected form small organic molecules.
- FIGURES are a diagrammatic representation of FIGURES.
- Table II sepsis criteria adapted from the sepsis score used in human medicine (Singer et al.,
- Blood proteins were extracted according to the protocol used by lin and collaborators. Western blots were performed on the protein extracts using an antibody directed against the O- GlcNAc (201995 Abeam). Briefly proteins were quantified using a BCA protein assay kit. 25 mg of each sample was separated on an SDS-PAGE gel and transferred to a nitrocellulose membrane. The membranes were blocked with 3% Bovine serum albumin (BSA) in TBS IX - Tween 0.5X (TBS-T) and then incubated with Anti-O-Linked N-acetylglucosamine antibody (clone RL2, 1 :20 000) overnight at 4°C. Analyses were performed using Image Lab software (Bio-Rad, California, United States). A ratio to the stain-free intensity was calculated.
- BSA Bovine serum albumin
- Table III Summary table of demographic and clinical data of horses included in the study. N represents the number of patients in each group. SD represents standard deviation. The rows labeled N-miss show the number of missing data. A 1-way Anova test was used. Study of O-GlcNAc levels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Inventors have used three cohorts of horses: a cohort consisting of healthy horses (n=20), a cohort consisting of horses hospitalized for colic without signs of sepsis until discharge (n=17) and horses hospitalized for colic with signs of sepsis (n=20). They performed western blot analysis and confirmed the presence of O-GlcNAc in the blood of the horses and showed that, that the O-GlcNAc levels in septic horses tended to decrease between admission and the first day (D1) after admission. This decrease became significant from the second day (D2) of hospitalization. Accordingly, the invention relates to a method for diagnosing whether a horse is at risk of or is susceptible to have a risk of sepsis comprising following steps: i) quantifying the expression level of O-GlcNAcylation in a biological sample obtained from the horse; ii) comparing the expression level quantified at step i) with its predetermined reference value; and iii) concluding that the horse is at risk of or is susceptible to have a risk of sepsis when the expression level of O-GlcNAcylation quantified at step i) is lower than its predetermined reference value.
Description
METHOD AND COMPOSITION FOR DETERMINING THE LEVEL OF O-
GLCNACYLATION IN HORSES
FIELD OF THE INVENTION:
The invention is in the field of horses, more particularly the invention relates to method and composition for determining the O-GlcNAcylation blood level in horses.
BACKGROUND OF THE INVENTION:
Digestive diseases (colic and diarrhea) are among the most important diseases in horses, both from a medical and economic point of view (Archer et Proudman 2006). They can be responsible for considerable economic and sporting losses for the equine sector due to their frequency and possible complications (Taylor 2015). While in many cases they resolve with medical treatment in the field, for some horses they can become the leading cause of death, especially when associated with a serious complication such as sepsis. It is defined as organ dysfunction caused by a deregulated host response to infection (Singer et al., 2016). As for human, cardiovascular shock secondary to sepsis generates organic dysfunctions that can lead to acute cardiac decompensation and endothelial dysfunction (disseminated intravascular coagulation, coagulopathies, etc.), which cause excess mortality. A few studies have looked at sepsis in horses with digestive diseases and have demonstrated its negative impact on survival prognosis (Roy et al., 2017 ; Borde et al., 2014 ; McConachie, Giguere, et Barton 2016). Indeed, more than 30% of horses with colic or diarrhea develop sepsis, and among them, about 40% die (Taylor 2015). Despite recent advances in the diagnosis and treatment of digestive disorders in horses, there are still many unknowns in sepsis. This has led to numerous scientific studies to understand its pathophysiology and to develop new diagnostic, prognostic and therapeutic strategies.
SUMMARY OF THE INVENTION:
The invention relates to a method for diagnosing whether a horse is at risk of or is susceptible to have a risk of sepsis comprising following steps: i) quantifying the expression level of O-GlcNAcylation in a biological sample obtained from the horse; ii) comparing the expression level quantified at step i) with its predetermined reference value; and
iii) concluding that the horse is at risk of or is susceptible to have a risk of sepsis when the expression level of O-GlcNAcylation quantified at step i) is lower than its predetermined reference value.
In particular, the invention is defined by the claims.
DETAILED DESCRIPTION OF THE INVENTION:
Inventors have used three cohorts of horses: a cohort consisting of healthy horses (n=20), a cohort consisting of horses hospitalized for colic without signs of sepsis until discharge (n=17) and horses hospitalized for colic with signs of sepsis (n=20). Blood sample and clinical data were collected at admission to the equine emergency service of Oniris and during the 3 first days of hospitalization. O-GlcNAc levels in blood were evaluated by western blot. Data were analyzed with ImageLab and Prism software.
Their analysis confirms the presence of O-GlcNAc in blood of horses. At admission O- GlcNAc levels are 2 times higher in colic induced sepsis group than in control or colic groups (control 0.65±0.42; colic 0.55±0.13; sepsis 1.09±0.35, p<0.05 Mann-Whitney test). O-GlcNAc levels decrease by 80% over time in septic horses (p<0.05 One way-ANOVA test).
O-GlcNAc levels in septic horses tended to decrease between admission and the first day (DI) after admission. This decrease became significant from the second day (D2) of hospitalization (Control D2: 80.52 ± 52.04; Sepsis D2: 27.86 ± 28.40, p < 0.05; Control D3: 84.91 ± 51.30; Sepsis D3: 27.86 ± 30.33, p < 0.01 Two way ANOVA test with repeated measure).
Accordingly, inventors have demonstrated that the O-GlcNAc levels in septic horses tended to decrease between admission and the first day (DI) after admission. This decrease became significant from the second day (D2) of hospitalization.
Accordingly, in a first aspect, the invention relates to a method for diagnosing whether a horse is at risk of or is susceptible to have a risk of sepsis comprising following steps: i) quantifying the expression level of O-GlcNAcylation in a biological sample obtained from the horse; ii) comparing the expression level quantified at step i) with its predetermined reference value; and iii) concluding that the horse is at risk of or is susceptible to have a risk of sepsis when the expression level of O-GlcNAcylation quantified at step i) is lower than its predetermined reference value.
In a particular embodiment, the invention relates to a method for diagnosing whether a horse is at risk of or is susceptible to have a risk of sepsis comprising following steps: i) quantifying the expression level of O-GlcNAcylation in a biological sample obtained from the horse at the admission and/or at the first day (DI) after admission; ii) quantifying the expression level of O-GlcNAcylation in a biological sample obtained from the horse at 2h, 4h, 6h, 8h, lOh, 12h, 14h, 16h, 18h, 20h, 22h, 24h, 26h, 28h, 30h, 32h, 34h, 36h, 38h, 40h, 42h, 44h, 44h, 46h or 48h after admission; iii) comparing the expression level quantified at step i) with the expression level quantified at step ii) and iv) concluding that the horse is at risk of or is susceptible to have a risk of sepsis when the expression level of O-GlcNAcylation is lower at step ii) than the expression level quantified at step i) or concluding that the horse is not at risk of or is not susceptible to have a risk of sepsis when the expression level of O-GlcNAcylation quantified at step ii) is higher than the expression level quantified at step i).
In a particular embodiment, the method according to the invention, wherein the step ii) is performed at second day (D2) after admission.
As used herein term “diagnosing” refers to classifying a disease or a symptom, determining a severity of the disease, monitoring disease progression, forecasting an outcome of a disease and/or prospects of recovery. The present invention relates to a method for diagnosing sepsis in a horse.
As used herein, the term “sepsis” means morbid condition induced by a toxin, the introduction or accumulation of which is caused by infection or trauma, and includes the early stage of sepsis, severe sepsis and the acute phase of septic shock. Sepsis is one of the complication of colic. The term “colic” encompasses all forms of gastrointestinal conditions which cause pain as well as other causes of abdominal pain not involving the gastrointestinal tract. The most common forms of colic are gastrointestinal in nature and are most often related to colonic disturbance.
The term “early stage sepsis” refers to the stage of the disease with the onset of clinical symptoms of severe infectious disease that typically include chills, profuse sweat, irregularly remittent fever, prostration and the like.
The term “severe sepsis” refers to the stage of the disease with the clinical symptoms of early stage sepsis in addition to persistent fever, lymphopenia, disseminated intravascular coagulation, respiratory distress syndrome, multiple organ failure and hypotension leading to shock.
The term “acute phase of septic shock” refers to peripheral circulatory collapse, resulting in hemodynamic, metabolic and visceral disorders that almost invariably lead to death.
As used herein, the term “risk” refers to the probability that an event will occur over a specific time period, as in the conversion to sepsis, and can mean a subject's "absolute" risk or "relative" risk. Absolute risk can be measured with reference to either actual observation postmeasurement for the relevant time cohort, or with reference to index values developed from statistically valid historical cohorts that have been followed for the relevant time period. Relative risk refers to the ratio of absolute risks of a subject compared either to the absolute risks of low risk cohorts or an average population risk, which can vary by how clinical risk factors are assessed. Odds ratios, the proportion of positive events to negative events for a given test result, are also commonly used (odds are according to the formula p/(l- p) where p is the probability of event and (1- p) is the probability of no event) to no conversion. Alternative continuous measures, which may be assessed in the context of the present invention, include time to sepsis conversion risk reduction ratios.
"Risk evaluation," or "evaluation of risk" in the context of the present invention encompasses making a prediction of the probability, odds, or likelihood that an event or disease state may occur, the rate of occurrence of the event or conversion from one disease state to another, i.e., from a normal condition to a sepsis condition or to one at risk of developing a sepsis. Risk evaluation can also comprise prediction of future clinical parameters, traditional laboratory risk factor values, or other indices of sepsis, such as cellular population determination in peripheral tissues, in serum or other fluid, either in absolute or relative terms in reference to a previously measured population. The methods of the present invention may be used to make continuous or categorical measurements of the risk of conversion to sepsis, thus diagnosing and defining the risk spectrum of a category of subjects defined as being at risk for a sepsis. In the categorical scenario, the invention can be used to discriminate between normal and other subject cohorts at higher risk for sepsis. In other embodiments, the present invention may be used so as to help to discriminate those having sepsis from normal.
As used herein, the term “O-GlcNAcylation” also known as O-N-acetyl glucosaminylation refers to a reversible posttranslational modification (PTM) that involves the addition of the monosaccharide b-D-Nacetylglucosamine to serine and threonine residues of proteins. Protein O-GlcNAcylation is catalyzed by O-GlcNAc transferase (OGT), and the O- GlcNAc group on proteins can be removed with the catalysis of P-N-acetylglucosaminidase (O- GlcNAcase, OGA). O-GlcNAcylation is regulated dynamically by these two enzymes and by the intracellular concentration of UDP-GlcNAc, a product of glucose metabolism through the hexosamine biosynthetic pathway (HBP).
As used herein, the term “level of O-GlcNAcylation” refers to the expression or level of O-GlcNAcylation in the biological sample. Typically, the said expression level may be expressed as any arbitrary unit that reflects the amount of the protein of interest that has been detected in the biological sample, such as intensity of a radioactive or of a fluorescence signal emitted by a labeled antibody specifically bound to the protein of interest. Alternatively, the value obtained at the end of step a) may consist of a concentration of protein(s) of interest that could be measured by various protein detection methods well known in the art, such as ELISA, SELDI-TOF, FACS or Western blotting. Typically, blood proteins were extracted according to the protocol used by lin and collaborators. Western blots were performed on the protein extracts using an antibody directed against the O-GlcNAc (Ac-RL2-HRP ref : 201995 Abeam). Briefly proteins were quantified using a BCA protein assay kit. 25 mg of each sample was separated on an SDS-PAGE gel and transferred to a nitrocellulose membrane. The membranes were blocked with 3% Bovine serum albumin (BSA) in TBS IX -Tween 0.5X (TBS-T) and then incubated with Anti-O-Linked N-acetylglucosamine antibody (clone RL2, 1 :20 000) overnight at 4°C. Analyses were performed using Image Lab software (Bio-Rad, California, United States). A ratio to the stain-free intensity was calculated.
In a particular embodiment, the horse is at risk of or is susceptible to have a risk of sepsis when the level of O-GlcNAcylation decreases at two days after admission at hospital.
As used herein, the term “biological sample” refers to any sample obtained from a horse, such as a serum sample, a plasma sample, a urine sample, a blood sample, a lymph sample, or a tissue sample. In a particular embodiment, the biological sample is a blood sample obtained from the horse.
As used herein, the term “predetermined reference value” refers to a threshold value or a cut-off value. In the context of the invention, the predetermined reference value refers to the expression level of O-GlcNAcylation measured at step i). Typically, the predetermined reference value corresponds to the level of O-GlcNAc level at the admission.
In a particular embodiment, the expression level of O-GlcNAcylation measured at step i) relates to the quantification of O-GlcNAc level at admission and/or the first day (DI) after admission.
In a particular embodiment, the expression level of O-GlcNAcylation measured at step ii) relates to the quantification of O-GlcNAc level at second day (D2) of hospitalization.
Typically, a "threshold value" or "cut-off value" can be determined experimentally, empirically, or theoretically. A threshold value can also be arbitrarily selected based upon the existing experimental and/or clinical conditions, as would be recognised by a person of ordinary skilled in the art. For example, retrospective measurement of the O-GlcNAcylation level in properly banked historical subject samples may be used in establishing the reference value. The threshold value has to be determined in order to obtain the optimal sensitivity and specificity according to the function of the test and the benefit/risk balance (clinical consequences of false positive and false negative). Typically, the optimal sensitivity and specificity (and so the threshold value) can be determined using a Receiver Operating Characteristic (ROC) curve based on experimental data. The full name of ROC curve is receiver operator characteristic curve, which is also known as receiver operation characteristic curve. It is mainly used for clinical biochemical diagnostic or prognostic tests. ROC curve is a comprehensive indicator that reflects the continuous variables of true positive rate (sensitivity) and false positive rate (1- specificity). It reveals the relationship between sensitivity and specificity with the image composition method. A series of different cut-off values (thresholds or critical values, boundary values between normal and abnormal results of diagnostic test) are set as continuous variables to calculate a series of sensitivity and specificity values. Existing software or systems in the art may be used for the drawing of the ROC curve, such as: MedCalc 9.2.0.1 medical statistical software, SPSS 9.0, ROCPOWER.SAS, DESIGNROC.FOR, MULTIREADER POWER. SAS, CREATE-ROC.SAS, GB STAT VIO.O (Dynamic Microsystems, Inc. Silver Spring, Md., USA), Stata/Se version 12.0 software (StataCorp LP, College Station, TX, USA), etc.
In some embodiments, the reference value is the level of O-GlcNAcylation in a healthy subject (i.e that has not been diagnosed for a sepsis).
In some embodiments, the reference value is the level of O-GlcNAcylation detected in previous samples obtained from the subject. In some embodiment, the reference value is the upper limit of values determined in healthy subjects (i.e that has not been diagnosed for a sepsis).
In a second aspect, the invention relates to a method for increasing O-GlcNAcylation levels in a horse having or is susceptible to have a sepsis comprising administering said horse with a therapeutically effective amount of a compound that increases O-GlcNAcylation level.
In other words, the invention relates to a method for treating sepsis in a horse comprising administering said horse with a therapeutically effective amount of a compound that increases O-GlcNAcylation level.
In a particular embodiment, the method according to the invention wherein the horse is diagnosed as having a risk of sepsis according to the method described as above.
In a particular embodiment, the method according to the invention wherein the compound that increases O-GlcNAcylation level is administered when the horse has a low expression level of O-GlcNAcylation during the second time.
As used herein, the term “increasing” refers to an increase in O-GlcNAcylation levels. In the context of the invention (sepsis in horse), an increase in O-GlcNAcylation levels allows to reduce production of lactates, creatininemia and blood urea nitrogen (BUN) and arterial bicarbonates.
As used herein, the term “compound that increases O-GlcNAcylation levels” refers to a natural or synthetic compound that has a biological effect to increase the levels of - GlcNAcylation.
In a particular embodiment, the compound that increases O-GlcNAcylation levels is a peptide, peptidomimetic or a small organic molecule.
In a particular embodiment, the compound that increases O-GlcNAcylation levels is a small organic molecule. The term “small organic molecule” refers to a molecule of a size comparable to those organic molecules generally used in pharmaceuticals. The term excludes biological macromolecules (e.g., proteins, nucleic acids, etc.). Preferred small organic molecules range in size up to about 5000 Da, more preferably up to 2000 Da, and most preferably up to about 1000 Da.
In a particular embodiment, the compound that increases O-GlcNAcylation levels is 1,2- dideoxy-2z -propyl- a -d-glucopyranoso-[2, 1-D]- A 2-thiazoline (NButGT) and its derivatives. The CAS number of NButGT is 863918-55-2.
In a particular embodiment, the compound that increases O-GlcNAcylation levels is (3aR,5R,6S,7R,7aR)-2-(ethylamino)-3a,6,7,7a-tetrahydro-5-(hydroxymethyl)-5H-Pyrano[3,2- d]thiazole-6,7-diol) (ThiametG) and its derivatives. The CAS number of ThiametG is 1009816- 48-1.
In a particular embodiment, the compound that increases O-GlcNAcylation levels is a compound that increases the Uridine diphosphate N-acetylglucosamine (UDP-GlcNAc).
As used herein, the term “UDP-GlcNAc” refers to a nucleotide sugar and a coenzyme in metabolism. It is synthesized de novo from glucose by the hexosamine synthesis pathway (HXBP), but can also be produced via salvage pathways.
In a particular embodiment, the compound that increases O-GlcNAcylation levels is UDP-GlcNAc.
In a particular embodiment, compound that increases O-GlcNAcylation levels is a ccompound that increases the hexosamine biosynthesis pathway flux that bypasses glutamine/fructose-6-phosphate amidotransferase 2.
In a particular embodiment, the compound that increases O-GlcNAcylation levels is glutamine or glucosamine.
In a particular embodiment, the compound that increases O-GlcNAcylation levels is an inhibitor of O-GlcNAcase (OGA).
As used herein, the term “O-GlcNAcase” is an enzyme with systematic name (protein)- 3-O-(N-acetyl-D-glucosaminyl)-L-serine/threonine N-acetylglucosaminyl hydrolase. OGA is encoded by the OGA gene. This enzyme catalyzes the removal of the O-GlcNAc post- translational modification. OGA catalyzes O-GlcNAc hydrolysis via an oxazoline reaction intermediate.
Inhibitor of OGA is well known in the art. Tests for determining the capacity of a compound to be OGA inhibitor are well known to the person skilled in the art. In a preferred embodiment, the inhibitor specifically binds to OGA in a sufficient manner to inhibit the biological activity of OGA. Binding to OGA and inhibition of the biological activity OGA may be determined by any competing assays well known in the art. For example, the assay may consist in determining the ability of the agent to be tested as OGA inhibitor to bind to OGA.
The binding ability is reflected by the Kd measurement. . The term "KD", as used herein, is intended to refer to the dissociation constant, which is obtained from the ratio of Kd to Ka (i.e. Kd/Ka) and is expressed as a molar concentration (M). KD values for binding biomolecules can be determined using methods well established in the art.
In a particular embodiment, the inhibitor of OGA is selected from the group consisting of but not limited to: MK-8719, LY3372689 or ASN-120,290 and their derivatives.
In a particular embodiment, the inhibitor of OGA is MK-8719 as described in Seinick et al 2019 (DOI: 10.1021/acs.jmedchem.9b01090; J. Med. Chem. 2019, 62, 10062-10097).
In a particular embodiment, the inhibitor of OGA is LY3372689 as described in WO2018/140299 and in Shcherbinin et al 2020 (Alzheimer's & Dementia: The Journal of the Alzheimer's Association , Dec2020 Supplement SI 1, Vol. 16 Issue 11, pl-2, 2p. Publisher: John Wiley & Sons, Inc).
In a particular embodiment, the inhibitor of OGA is ASN-120,290 (previously ASN- 561) as described in WO2017/144639.
In a particular embodiment, the inhibitor of OGA is described in W02006/092049, WO 2008/025170, W02010/012106, WO2010/012106, W02010/012107, WO2010/037207, WO201 1/140640, W02012/064680, WO2012/083435, WO2013/166654, W02014/100934, WO2014/032184, WO2014/032185, WO2014/032187, WO2014/067003, WO2017106254, and WO2022/108377..
As used herein the terms "administering" or "administration" refer to the act of injecting or otherwise physically delivering a substance as it exists outside the body (e.g., a compound that increases O-GlcNAcylation levels) into the subject, such as by mucosal, intradermal, intravenous, subcutaneous, intramuscular delivery and/or any other method of physical delivery described herein or known in the art. When a disease, or a symptom thereof, is being treated, administration of the substance typically occurs after the onset of the disease or symptoms thereof. When a disease or symptoms thereof, are being prevented, administration of the substance typically occurs before the onset of the disease or symptoms thereof.
A “therapeutically effective amount” is intended for a minimal amount of active agent which is necessary to impart therapeutic benefit to a subject. For example, a "therapeutically effective amount" to a subject is such an amount which induces, ameliorates or otherwise causes an improvement in the pathological symptoms, disease progression or physiological conditions associated with or resistance to succumbing to a disorder. It will be understood that the total
daily usage of the compounds of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific compound 15 employed; the specific composition employed, the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of the compound at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. However, the daily dosage of the products may be varied over a wide range from 0.01 to 1,000 mg per adult per day. Typically, the compositions contain 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 250 and 500 mg of the active ingredient for the symptomatic adjustment of the dosage to the subject to be treated. A medicament typically contains from about 0.01 mg to about 500 mg of the active ingredient, preferably from 1 mg to about 100 mg of the active ingredient. An effective amount of the drug is ordinarily supplied at a dosage level from 0.0002 mg/kg to about mg/kg of body weight per day, especially from about 0.001 mg/kg to 7 mg/kg of body weight per day.
The compound that increases O-GlcNAcylation levels as described above may be combined with pharmaceutically acceptable excipients, and optionally sustained-release matrices, such as biodegradable polymers, to form pharmaceutical compositions.
Accordingly, in a third aspect, the invention relates to a pharmaceutical composition comprising a compound that increases O-GlcNAcylation levels.
In particular embodiment, the invention relates to the pharmaceutical composition comprising a compound that increases O-GlcNAcylation levels for use in the treatment of sepsis in horse.
In particular embodiment, the invention relates to a pharmaceutical composition comprising the compound that increases O-GlcNAcylation levels as described above and excipients.
"Pharmaceutically" or "pharmaceutically acceptable" refer to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to a mammal, especially a human, as appropriate. A pharmaceutically acceptable
carrier or excipient refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The pharmaceutical compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, transdermal, local or rectal administration, the active principle, alone or in combination with another active principle, can be administered in a unit administration form, as a mixture with conventional pharmaceutical supports, to animals and human beings. Suitable unit administration forms comprise oral-route forms such as tablets, gel capsules, powders, granules and oral suspensions or solutions, sublingual and buccal administration forms, aerosols, implants, subcutaneous, transdermal, topical, intraperitoneal, intramuscular, intravenous, subdermal, transdermal, intrathecal and intranasal administration forms and rectal administration forms. Typically, the pharmaceutical compositions contain vehicles which are pharmaceutically acceptable for a formulation capable of being injected. These may be in particular isotonic, sterile, saline solutions (monosodium or disodium phosphate, sodium, potassium, calcium or magnesium chloride and the like or mixtures of such salts), or dry, especially freeze-dried compositions which upon addition, depending on the case, of sterilized water or physiological saline, permit the constitution of injectable solutions. The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations including sesame oil, peanut oil or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. Solutions comprising compounds of the invention as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. The polypeptide (or nucleic acid encoding thereof) can be formulated into a composition in a neutral or salt form. Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like. The carrier can also be a solvent or dispersion medium containing, for example, water,
ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetables oils. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminium monostearate and gelatin. Sterile injectable solutions are prepared by incorporating the active polypeptides in the required amount in the appropriate solvent with several of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective. The formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above, but drug release capsules and the like can also be employed. For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, sterile aqueous media which can be employed will be known to those of skill in the art in light of the present disclosure. For example, one dosage could be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion. Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.
In a particular embodiment, the invention relates to a pharmaceutical composition comprising NButGT in the context of sepsis in horse.
In a particular embodiment, the invention relates to a pharmaceutical composition comprising ThiametG in the context of sepsis in horse.
In a particular embodiment, the invention relates to a pharmaceutical composition comprising glutamine or glucosamine in the context of sepsis in horse.
In a particular embodiment, the invention relates to a pharmaceutical composition comprising MK-8719, LY3372689 or ASN-120,290 and their derivatives
A further object of the present invention relates to a method of screening a compound that increases O-GlcNAcylation levels comprising i) providing a test compound and ii) determining the ability of said test compound to increase O-GlcNAcylation levels.
Any biological assay well known in the art could be suitable for determining the ability of the test compound to increase O-GlcNAcylation levels. In some embodiments, the assay first comprises determining the ability of the test compound to bind to a protein O-GlcNAcylation. In some embodiments, a population of cells is then contacted and activated so as to determine the ability of the test compound to increase O-GlcNAcylation. In particular, the effect triggered by the test compound is determined relative to that of a population of immune cells incubated in parallel in the absence of the test compound or in the presence of a control agent either of which is analogous to a negative control condition. The term "control substance", "control agent", or "control compound" as used herein refers a molecule that is inert or has no activity relating to an ability to modulate a biological activity or expression. It is to be understood that test compounds capable of increasing O-GlcNAcylation levels, as determined using in vitro methods described herein, are likely to exhibit similar modulatory capacity in applications in vivo. Typically, the test compound is small organic molecules. For example, the test compound according to the invention may be selected from a library of compounds previously synthesised, or a library of compounds for which the structure is determined in a database, or from a library of compounds that have been synthesised de novo. In some embodiments, the test compound may be selected form small organic molecules.
In a fourth aspect, the invention relates to a kit suitable diagnosis whether a horse is at risk of or is susceptible to have a risk of sepsis comprising a reagent that specifically reacts with O-GlcNAcylation and instructions to perform the diagnosing method of sepsis according to the method as described above.
In another aspect, the invention relates to a method of screening a compound that increases O-GlcNAcylation levels comprising i) providing a test compound and ii) determining the ability of said test compound to increase O-GlcNAcylation levels.
Any biological assay well known in the art could be suitable for determining the ability of the test compound to increase the O-GlcNAcylation levels. In some embodiments, the assay first comprises determining the ability of the test compound to bind to O-GlcNAcylation level. In some embodiments, a population of cells is then contacted and activated so as to determine the ability of the test compound to increase the O-GlcNAcylation levels. In particular, the effect triggered by the test compound is determined relative to that of a population of immune cells incubated in parallel in the absence of the test compound or in the presence of a control agent either of which is analogous to a negative control condition. The term "control substance", "control agent", or "control compound" as used herein refers a molecule that is inert or has no activity relating to an ability to modulate a biological activity or expression. It is to be understood that test compounds capable of increasing the O-GlcNAcylation levels, as determined using in vitro methods described herein, are likely to exhibit similar modulatory capacity in applications in vivo. Typically, the test compound is selected from the group consisting of peptides, petptidomimetics, small organic molecules, aptamers or nucleic acids. For example, the test compound according to the invention may be selected from a library of compounds previously synthesised, or a library of compounds for which the structure is determined in a database, or from a library of compounds that have been synthesised de novo. In some embodiments, the test compound may be selected form small organic molecules. The invention will be further illustrated by the following figures and examples. However, these examples and figures should not be interpreted in any way as limiting the scope of the present invention.
The invention will be further illustrated by the following figures and examples. However, these examples and figures should not be interpreted in any way as limiting the scope of the present invention.
FIGURES:
Figure 1: Variation in blood O-GlcNAc levels of horses admitted with sepsis. Evaluation by western blot of O-GlcNAcylation levels of blood proteins throughout treatment (Controladmission, J1-8H, J2-8H and J3-8H, n = 20, Colic admission, J1-8H, J2-8H n = 17 and J3-8H n = 14, Sepsis admission n = 10, Jl-8H n=10, J2-8H n = 9 and J3-8H n= 8) Quantification of O-GlcNAcylationlevels is normalized to stain free. Results expressed as a mean ± SEM. Colic J2-8h vs Sepsis J2-8h, *p<0.05; Control J2 vs Sepsis J2, *p< 0.05 and Control J3-8h vs Sepsis J3-8h, ** p<0.01 Tow wayAnova test (Mixted effect model) with repeated mesure.
Figure 2: Variation in blood O-GlcNAc levels of horses admitted with sepsis. Evaluation by western blot of O-GlcNAcylation levels of blood proteins throughout treatment at admission. Control n=9, colique n=7, sepsis n=4, sepsis mort n=5. Quatification of O- GlcNAcylation levels is normalizedto stain free. Results expressed as a mean ± SEM. NS, Test one way Anova, post hoc test Bonferonni.
EXAMPLE:
Material & Methods
Horse Patient
Clinical routine data and blood samples were collected at the equine emergency service of Oniris. Horses admitted for digestive syndrome (also called colic) or diarrhea were included in the study. If these horses had a SIRS score greater than or equal to 4 (Table I) and a Multiple Organ Dysfunction Score (MODS) (Table II) greater than or equal to 6 then horses were considered to be in sepsis.
Table I : Scoring of systemic inflammatory response syndrome (SIRS)
Using these criteria, three cohorts were designed: a cohort consisting of healthy horses (n=20), a cohort consisting of horses hospitalized for colic without signs of sepsis until discharge (n=17) and horses hospitalized for colic with signs of sepsis (n=20). Blood samples and clinical data of healthy horses were collected at the Daniel Brother Agricultural High
Table II: sepsis criteria adapted from the sepsis score used in human medicine (Singer et al.,
2016) and the multi-organ dysfunction score described for horses in colic (McConachie, Giguere, et Barton 2016). To be included in one of the 2 sepsis groups in the study, horses 0 will need to have at least 2 criteria of exaggerated systemic inflammatory response syndrome (SIRS) and an organ dysfunction score >2.
Blood sampling and analyses
4-mL volume of arterial blood was collected on admission of the horse (TD) and then each morning for 3 days after admission (data not shown). Blood samples were placed in a 4 5 mL heparin tube. NFS and blood gases were performed on admission. Aliquots of 1.5 mL of whole blood were made and stored at -80°C.
Protein extraction and western blot analyses
Blood proteins were extracted according to the protocol used by lin and collaborators. Western blots were performed on the protein extracts using an antibody directed against the O-
GlcNAc (201995 Abeam). Briefly proteins were quantified using a BCA protein assay kit. 25 mg of each sample was separated on an SDS-PAGE gel and transferred to a nitrocellulose membrane. The membranes were blocked with 3% Bovine serum albumin (BSA) in TBS IX - Tween 0.5X (TBS-T) and then incubated with Anti-O-Linked N-acetylglucosamine antibody (clone RL2, 1 :20 000) overnight at 4°C. Analyses were performed using Image Lab software (Bio-Rad, California, United States). A ratio to the stain-free intensity was calculated.
Statistical analyses
Analyses of Western blots were expressed in relation to the average of the protein quantification (stain free) and then reduced to the average of the control samples. Data of O- GlcNAc level at admission and following levels of O-GlcNAc over time were analyzed with Mann Whitney test and with Kruskal-Wallis test with repeated measures, respectively.
Results
Demographic and clinic results: The demographic and clinical data of the horses included in the study are described in
Table III: Summary table of demographic and clinical data of horses included in the study. N represents the number of patients in each group. SD represents standard deviation. The rows labeled N-miss show the number of missing data. A 1-way Anova test was used. Study of O-GlcNAc levels
Western blot analysis confirmed the presence of O-GlcNAc in the blood of the horses and showed that, on admission of the horses to the veterinary emergency department.
In addition, O-GlcNAc levels decreased by 80% over time in septic horses (p<0.05 Kruskall Wallis test with repeated measures) (Figure 2).
Claims
1. A method for diagnosing whether a horse is at risk of or is susceptible to have a risk of sepsis comprising following steps: i) quantifying the expression level of O-GlcNAcylation in a biological sample obtained from the horse; ii) comparing the expression level quantified at step i) with its predetermined reference value; and iii) concluding that the horse is at risk of or is susceptible to have a risk of sepsis when the expression level of O-GlcNAcylation quantified at step i) is lower than its predetermined reference value.
2. The method according to claim 1, wherein the predetermined reference value corresponds to the level of O- GlcNAcylation level at the admission and/or the first day (DI) after admission.
3. The method according to claim 1, wherein the step ii) is performed at 2h, 4h, 6h, 8h, lOh, 12h, 14h, 16h, 18h, 20h, 22h, 24h, 26h, 28h, 30h, 32h, 34h, 36h, 38h, 40h, 42h, 44h, 44h, 46h or 48h after admission.
4. The method according to claim 1, where the step ii) is performed at second day (D2) after admission.
5. The method according to claim 1 wherein, the biological sample is blood sample.
6. A method for increasing O-GlcNAcylation levels in a horse having or is susceptible to have a sepsis comprising a step of administering said subject a therapeutically effective amount of a compound that increases O-GlcNAcylation levels.
7. The method according to claim 6 wherein, the compound that increases O- GlcNAcylation levels is l,2-dideoxy-2'-propyl-a-d-glucopyranoso-[2,l-D]-A2'- thiazoline (NButGT).
The method according to claim 6 wherein, the compound that increases O- GlcNAcylation levels is (3aR,5R,6S,7R,7aR)-2-(ethylamino)-3a,6,7,7a-tetrahydro-5- (hydroxymethyl)-5H-Pyrano[3,2-d]thiazole-6,7-diol) (ThiametG). The method according to claim 6 wherein, the compound that increases O- GlcNAcylation levels is a compound that increases Uridine diphosphate N- acetylglucosamine (UDP-GlcNAc). The method according to claim 6 wherein, the compound that increases O- GlcNAcylation levels is an inhibitor of O-GlcNAcase (OGA). The method according to claim 10 wherein, the inhibitor of OGA is selected from the group consisting of but not limited to: MK-8719, LY3372689 or ASN-120,290. The method according to claim 6 wherein, the compound that increases O- GlcNAcylation levels is glutamine or glucosamine. A pharmaceutical composition comprising a compound that increases O-GlcNAcylation levels for use in the treatment of sepsis in a horse. The pharmaceutical composition according to claim 13 wherein, the compound that increases O-GlcNAcylation levels is l,2-dideoxy-2'-propyl-a-d-glucopyranoso-[2,l- D]-A2'-thiazoline (NButGT), 3aR,5R,6S,7R,7aR)-2-(ethylamino)-3a,6,7,7a- tetrahydro-5-(hydroxymethyl)-5H-Pyrano[3,2-d]thiazole-6,7-diol) (ThiametG), Uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), glutamine , glucosamine or MK-8719, LY3372689 or ASN-120,290 and their derivatives. A method of screening a compound that increases O-GlcNAcylation levels comprising i) providing a test compound and ii) determining the ability of said test compound to increase O-GlcNAcylation levels.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22306576.4 | 2022-10-18 | ||
EP22306576 | 2022-10-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024083820A1 true WO2024083820A1 (en) | 2024-04-25 |
Family
ID=84331874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/078823 WO2024083820A1 (en) | 2022-10-18 | 2023-10-17 | Method and composition for determining the level of o-glcnacylation in horses |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024083820A1 (en) |
Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006092049A1 (en) | 2005-03-01 | 2006-09-08 | Simon Fraser University | Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof |
WO2008025170A1 (en) | 2006-08-31 | 2008-03-06 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
WO2010012106A1 (en) | 2008-08-01 | 2010-02-04 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
WO2010012107A1 (en) | 2008-08-01 | 2010-02-04 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
WO2010037207A1 (en) | 2008-09-16 | 2010-04-08 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
WO2011140640A1 (en) | 2010-05-11 | 2011-11-17 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
WO2012064680A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
WO2012083435A1 (en) | 2010-12-23 | 2012-06-28 | Alectos Therapeutics, Inc. | Selective glycosidase inhibitors and uses thereof |
WO2013000086A1 (en) * | 2011-06-27 | 2013-01-03 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
WO2013166654A1 (en) | 2012-05-08 | 2013-11-14 | Merck Sharp & Dohme Corp. | Permeable glycosidase inhibitors and uses thereof |
WO2014032187A1 (en) | 2012-08-31 | 2014-03-06 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
WO2014032184A1 (en) | 2012-08-31 | 2014-03-06 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
WO2014032185A1 (en) | 2012-08-31 | 2014-03-06 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
WO2014067003A1 (en) | 2012-10-31 | 2014-05-08 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
WO2014100934A1 (en) | 2012-12-24 | 2014-07-03 | Merck Sharp & Dohme Corp. | Glycosidase inhibitors and uses thereof |
WO2017106254A1 (en) | 2015-12-18 | 2017-06-22 | Merck Sharp & Dohme Corp. | Glycosidase inhibitors and uses thereof |
WO2017144639A1 (en) | 2016-02-25 | 2017-08-31 | Asceneuron S. A. | Glycosidase inhibitors |
WO2018140299A1 (en) | 2017-01-27 | 2018-08-02 | Eli Lilly And Company | N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor |
WO2021123297A1 (en) * | 2019-12-18 | 2021-06-24 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
WO2022108377A1 (en) | 2020-11-23 | 2022-05-27 | (주) 메디프론디비티 | Compound having inhibitory activity against o-glcnacase and use thereof |
-
2023
- 2023-10-17 WO PCT/EP2023/078823 patent/WO2024083820A1/en unknown
Patent Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006092049A1 (en) | 2005-03-01 | 2006-09-08 | Simon Fraser University | Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof |
WO2008025170A1 (en) | 2006-08-31 | 2008-03-06 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
WO2010012106A1 (en) | 2008-08-01 | 2010-02-04 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
WO2010012107A1 (en) | 2008-08-01 | 2010-02-04 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
WO2010037207A1 (en) | 2008-09-16 | 2010-04-08 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
WO2011140640A1 (en) | 2010-05-11 | 2011-11-17 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
WO2012064680A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
WO2012083435A1 (en) | 2010-12-23 | 2012-06-28 | Alectos Therapeutics, Inc. | Selective glycosidase inhibitors and uses thereof |
WO2013000086A1 (en) * | 2011-06-27 | 2013-01-03 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
WO2013166654A1 (en) | 2012-05-08 | 2013-11-14 | Merck Sharp & Dohme Corp. | Permeable glycosidase inhibitors and uses thereof |
WO2014032187A1 (en) | 2012-08-31 | 2014-03-06 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
WO2014032184A1 (en) | 2012-08-31 | 2014-03-06 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
WO2014032185A1 (en) | 2012-08-31 | 2014-03-06 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
WO2014067003A1 (en) | 2012-10-31 | 2014-05-08 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
WO2014100934A1 (en) | 2012-12-24 | 2014-07-03 | Merck Sharp & Dohme Corp. | Glycosidase inhibitors and uses thereof |
WO2017106254A1 (en) | 2015-12-18 | 2017-06-22 | Merck Sharp & Dohme Corp. | Glycosidase inhibitors and uses thereof |
WO2017144639A1 (en) | 2016-02-25 | 2017-08-31 | Asceneuron S. A. | Glycosidase inhibitors |
WO2018140299A1 (en) | 2017-01-27 | 2018-08-02 | Eli Lilly And Company | N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor |
WO2021123297A1 (en) * | 2019-12-18 | 2021-06-24 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
WO2022108377A1 (en) | 2020-11-23 | 2022-05-27 | (주) 메디프론디비티 | Compound having inhibitory activity against o-glcnacase and use thereof |
Non-Patent Citations (5)
Title |
---|
DUPAS T. ET AL.: "Beneficial effects of O-GlcNAc stimulation in a young rat model of sepsis: Beyond modulation of gene expression", INT. J. MOL. SCI., vol. 23, no. 12, 6430, 9 June 2022 (2022-06-09), pages 1 - 13, XP093032420 * |
FERRON M. ET AL.: "O-GlcNAc stimulation: A new metabolic approach to treat septic shock", SCI. REP., vol. 9, 18751, 10 December 2019 (2019-12-10), pages 1 - 13, XP093032427 * |
FERRON M. ET AL.: "Protein O-GlcNAcylation in cardiac pathologies: Past, present, future", FRONT. ENDOCRINOL., vol. 9, 819, 15 January 2019 (2019-01-15), pages 1 - 12, XP055959125 * |
SELNICK ET AL., J. MED. CHEM., vol. 62, 2019, pages 10062 - 10097 |
SHCHERBININ ET AL.: "Alzheimer's & Dementia: The Journal of the Alzheimer's Association", vol. 16, 2020, JOHN WILEY & SONS, INC, pages: 1 - 2 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jian et al. | Low-dose sorafenib acts as a mitochondrial uncoupler and ameliorates nonalcoholic steatohepatitis | |
Unoki-Kubota et al. | Pyridoxamine, an inhibitor of advanced glycation end product (AGE) formation ameliorates insulin resistance in obese, type 2 diabetic mice | |
CN103238070B (en) | Can regulate/protect the compound for preventing or treat Causes of Acute Traumatic coagulopathy and cardiopulmonary resuscitation of endothelium integrity | |
EP2846787A2 (en) | New methods | |
EP2834642A1 (en) | Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest | |
KR20180004818A (en) | Models, methods and compositions for the treatment of inflammatory bowel disease | |
JP2021508711A (en) | Pharmaceutical composition containing APL-type peptide | |
JP2021152087A (en) | Ado-resistant cysteamine analogs and uses thereof | |
Zheng et al. | Lidocaine alleviates sepsis-induced acute lung injury in mice by suppressing tissue factor and matrix metalloproteinase-2/9 | |
US20150335612A1 (en) | Artemisinin And Its Derivatives For Use In The Treatment Of Kidney Disease | |
WO2018009555A1 (en) | Compounds, compositions and methods for preventing and/or treating inflammation and/or organ dysfunction after pediatric cardiovascular surgery | |
Cass et al. | Effect of renal impairment on the pharmacokinetics of intravenous zanamivir | |
WO2024083820A1 (en) | Method and composition for determining the level of o-glcnacylation in horses | |
Arnout et al. | Effectiveness and tolerability of CV‐3988, a selective PAF antagonist, after intravenous administration to man. | |
CN113304133A (en) | Application of kaurane compounds in preparation of medicines for preventing and treating inflammatory bowel diseases | |
US8530455B2 (en) | Hemostatic effects of glucono-delta-lactone | |
US20200377518A1 (en) | Method of preventing and treating thrombosis | |
WO2003070235A1 (en) | Medicinal compositions for inhibiting tryptase | |
Kodama et al. | No effect of gender or age on binding characteristics of valproic acid to serum proteins in pediatric patients with epilepsy | |
CN114948855B (en) | Nasal administration scutellarin magnesium temperature-sensitive in-situ gel preparation and preparation method thereof | |
TWI785853B (en) | Use of composition for treating hypertension | |
JP2004532415A (en) | Methods and kits for in vitro diagnosis or monitoring of diseases involving inflammatory reactions | |
WO2022039206A1 (en) | Pharmaceutical composition for treating non-alcoholic steatohepatitis | |
WO2023061946A1 (en) | Use of trem-1 for predicting and preventing postoperative complications after cardiac surgery with cardiopulmonary by-pass | |
US20210052617A1 (en) | Methods and compositions for treating pre-eclampsia |